RXElite Stock

RXElite ROE

The Return on Equity (ROE) of RXElite (RXEI) as of Aug 12, 2026 is -139.48 %.

ROE

-139.48 %

Last updated:

In 2026, RXElite's return on equity (ROE) was -139.48 %, a % increase from the - ROE in the previous year.

Access this data via the Eulerpool API

RXElite Stock analysis

What does RXElite do? RXElite Inc is a US-based company operating in the pharmaceutical and biotechnology sector. The company was founded in 1999 and is headquartered in Phoenix, Arizona. RXElite Inc specializes in the manufacturing and marketing of innovative medications and therapies developed and produced for both the American and international markets. RXElite Inc has various divisions and business sectors that focus on different demand patterns within the pharmaceutical and biotech industry. One area in which the company operates is the manufacturing of prescription medications, including prescription pain relievers and medications for inflammation and other diseases. Furthermore, RXElite Inc is involved in the development and manufacturing of generic drugs, which have the same active ingredient composition as existing brand-name medications. Generics are typically more affordable than brand-name medications and can result in cost savings for patients. Another business segment of RXElite Inc is the production of dietary supplements and vitamin preparations. The company uses natural ingredients and emphasizes high quality to meet the increasing demands of customers. RXElite Inc also operates in the field of medical device development and marketing, aiming to improve the diagnosis and treatment of diseases. This includes devices for measuring blood pressure or blood sugar levels, as well as ventilators. The RXElite Inc business model is diversified, aiming to meet existing market needs and explore new market segments. The company combines research, development, and production to provide customers with innovative and high-quality products. In recent years, RXElite Inc has expanded its portfolio and strengthened its position in the pharmaceutical and biotech sector through various acquisitions and partnerships. One important acquisition was the takeover of American Wholesale Distributors in 2006, which provided RXElite Inc with access to a broader customer base and new markets. International expansion is another focus of RXElite Inc. The company has opened several branches in Asia, Europe, and Latin America to increase its market share and expand its global presence. RXElite Inc places great emphasis on innovation and research and development. The company continuously invests in the exploration of new active ingredients and manufacturing processes for medications. RXElite Inc also has strong partnerships with various universities and research institutions to strengthen collaboration and promote the exchange of ideas and expertise. Overall, RXElite Inc is a dynamic and diversified company that occupies a leading position in the pharmaceutical and biotech sector due to its comprehensive portfolio of products and services, as well as its global reach. RXElite Inc strives to meet the needs of its customers and strengthen its position in the market through continuous innovation and expansion. RXElite is one of the most popular companies on Eulerpool.

ROE Details

Decoding RXElite's Return on Equity (ROE)

RXElite's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing RXElite's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

RXElite's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in RXElite’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about RXElite stock

Return on Equity (ROE) of RXElite is -139.48 % in 2026.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) RXElite since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s RXElite with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

Profitability — RXElite

All Key Metrics — RXElite